- Home
- BWIN vs SVRA Comparison
BWIN vs SVRA Comparison
Compare BWIN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.44
Company Overview
Basic Information| Metric | BWIN | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BWIN | SVRA |
|---|---|---|
| Price | $22.46 | $6.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $38.43 | $6.88 |
| AVG Volume (30 Days) | 1.2M | ★ 3.2M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,487,497,000.00 | N/A |
| Revenue This Year | $10.87 | N/A |
| Revenue Next Year | $10.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.69 | N/A |
| 52 Week Low | $21.26 | $1.89 |
| 52 Week High | $47.15 | $7.01 |
Technical Indicators
Market Signals| Indicator | BWIN | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 65.69 |
| Support Level | $21.78 | $6.39 |
| Resistance Level | $24.91 | $7.01 |
| Average True Range (ATR) | 1.57 | 0.47 |
| MACD | -0.36 | 0.01 |
| Stochastic Oscillator | 9.75 | 69.97 |
Price Performance
Historical Comparison BWIN
SVRA
About BWIN The Baldwin Insurance Group Inc.
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.